Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer
Corresponding Author
Masaki Shiota M.D., Ph.D.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorRyo Namitome M.D.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorTakeshi Kobayashi M.D.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorJunichi Inokuchi M.D., Ph.D.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorKatsunori Tatsugami M.D., Ph.D.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorMasatoshi Eto M.D., Ph.D.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorCorresponding Author
Masaki Shiota M.D., Ph.D.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorRyo Namitome M.D.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorTakeshi Kobayashi M.D.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorJunichi Inokuchi M.D., Ph.D.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorKatsunori Tatsugami M.D., Ph.D.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorMasatoshi Eto M.D., Ph.D.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Search for more papers by this authorConflict of interest
None declared.
Supporting Information
| Filename | Description |
|---|---|
| iju13870-sup-0001-sm_f1.jpgimage/jpg, 1.1 MB | Figure S1. Categorization of men with metastatic prostate cancer using the CHAARTED and LATITUDE risk definition criteria. |
| iju13870-sup-0002-sm_t1.xlsxMS Excel, 12.8 KB | Table S1. Patient characteristics stratified by risk classification in the CHAARTED and LATITUDE trials. |
| iju13870-sup-0003-sm_t2.xlsxMS Excel, 13 KB | Table S2. Associations between clinicopathological parameters and PFS. |
| iju13870-sup-0004-sm_t3.xlsxMS Excel, 13 KB | Table S3. Associations between clinicopathological parameters and overall survival. |
| iju13870-sup-0005-sm_t4.xlsxMS Excel, 12.5 KB | Table S4. Published data on time to castration-resistant prostate cancer and overall survival according to risk stratification. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Kyriakopoulos CE, Chen YH, Carducci MA et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol. 2018; 36: 1080–7.
- 2Fizazi K, Tran N, Fein L et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 2017; 377: 352–60.
- 3Bernard B, Muralidhar V, Chen YH et al. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer 2017; 123: 1536–44.
- 4Miyoshi Y, Noguchi K, Yanagisawa M et al. Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer. BMC Cancer 2015; 15: 338.
- 5Gravis G, Boher JM, Chen YH et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur. Urol. 2018; 73: 847–55.
- 6Francini E, Gray KP, Xie W et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 2018; 78: 889–95.
- 7Buelens S, Poelaert F, Dhondt B et al. Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing definitions of CHAARTED and LATITUDE trial. Urol. Oncol. 2018; 36: e13–20.
Citing Literature
